Literature DB >> 25568918

The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer.

Douglas K Graham, Deborah DeRyckere, Kurtis D Davies, H Shelton Earp.   

Abstract

The TYRO3, AXL (also known as UFO) and MERTK (TAM) family of receptor tyrosine kinases (RTKs) are aberrantly expressed in multiple haematological and epithelial malignancies. Rather than functioning as oncogenic drivers, their induction in tumour cells predominately promotes survival, chemoresistance and motility. The unique mode of maximal activation of this RTK family requires an extracellular lipid–protein complex. For example, the protein ligand, growth arrest-specific protein 6 (GAS6), binds to phosphatidylserine (PtdSer) that is externalized on apoptotic cell membranes, which activates MERTK on macrophages. This triggers engulfment of apoptotic material and subsequent anti-inflammatory macrophage polarization. In tumours, autocrine and paracrine ligands and apoptotic cells are abundant, which provide a survival signal to the tumour cell and favour an anti-inflammatory, immunosuppressive microenvironment. Thus, TAM kinase inhibition could stimulate antitumour immunity, reduce tumour cell survival, enhance chemosensitivity and diminish metastatic potential.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25568918     DOI: 10.1038/nrc3847

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  195 in total

Review 1.  Protein S: A multifunctional anticoagulant vitamin K-dependent protein at the crossroads of coagulation, inflammation, angiogenesis, and cancer.

Authors:  Lutfi Suleiman; Claude Négrier; Habib Boukerche
Journal:  Crit Rev Oncol Hematol       Date:  2013-08-16       Impact factor: 6.312

2.  Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA.

Authors:  Mark Mackiewicz; Konrad Huppi; Jason J Pitt; Tiffany H Dorsey; Stefan Ambs; Natasha J Caplen
Journal:  Breast Cancer Res Treat       Date:  2011-08-04       Impact factor: 4.872

3.  Increased hematopoietic cells in the mertk-/- mouse peritoneal cavity: a result of augmented migration.

Authors:  Julie C Williams; Nikki J Wagner; H Shelton Earp; Barbara J Vilen; Glenn K Matsushima
Journal:  J Immunol       Date:  2010-05-14       Impact factor: 5.422

4.  A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors.

Authors:  D Mahadevan; L Cooke; C Riley; R Swart; B Simons; K Della Croce; L Wisner; M Iorio; K Shakalya; H Garewal; R Nagle; D Bearss
Journal:  Oncogene       Date:  2007-02-26       Impact factor: 9.867

5.  The cellular and molecular origin of tumor-associated macrophages.

Authors:  Ruth A Franklin; Will Liao; Abira Sarkar; Myoungjoo V Kim; Michael R Bivona; Kang Liu; Eric G Pamer; Ming O Li
Journal:  Science       Date:  2014-05-08       Impact factor: 47.728

6.  Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer.

Authors:  Kenneth Macleod; Peter Mullen; Jane Sewell; Genevieve Rabiasz; Sandra Lawrie; Eric Miller; John F Smyth; Simon P Langdon
Journal:  Cancer Res       Date:  2005-08-01       Impact factor: 12.701

7.  Adhesion-related kinase repression of gonadotropin-releasing hormone gene expression requires Rac activation of the extracellular signal-regulated kinase pathway.

Authors:  Melissa P Allen; Mei Xu; Daniel A Linseman; John E Pawlowski; Gary M Bokoch; Kim A Heidenreich; Margaret E Wierman
Journal:  J Biol Chem       Date:  2002-07-22       Impact factor: 5.157

8.  UNC1062, a new and potent Mer inhibitor.

Authors:  Jing Liu; Weihe Zhang; Michael A Stashko; Deborah Deryckere; Christopher T Cummings; Debra Hunter; Chao Yang; Chatura N Jayakody; Nancy Cheng; Catherine Simpson; Jacqueline Norris-Drouin; Susan Sather; Dmitri Kireev; William P Janzen; H Shelton Earp; Douglas K Graham; Stephen V Frye; Xiaodong Wang
Journal:  Eur J Med Chem       Date:  2013-04-02       Impact factor: 6.514

9.  Tumor-associated macrophages promote oral cancer progression through activation of the Axl signaling pathway.

Authors:  Chien-Hsing Lee; Shyun-Yeu Liu; Kuo-Chou Chou; Chi-Tai Yeh; Shine-Gwo Shiah; Ren-Yeong Huang; Jen-Chan Cheng; Ching-Yu Yen; Yi-Shing Shieh
Journal:  Ann Surg Oncol       Date:  2013-11-26       Impact factor: 5.344

10.  Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia.

Authors:  A B Lee-Sherick; K M Eisenman; S Sather; A McGranahan; P M Armistead; C S McGary; S A Hunsucker; J Schlegel; H Martinson; C Cannon; A K Keating; H S Earp; X Liang; D DeRyckere; D K Graham
Journal:  Oncogene       Date:  2013-03-11       Impact factor: 9.867

View more
  253 in total

1.  Role of sphingosine 1-phosphate in human pancreatic cancer cells proliferation and migration.

Authors:  Yun-Xia Guo; Ying-Jie Ma; Li Han; Yu-Jie Wang; Ji-Ao Han; Ying Zhu
Journal:  Int J Clin Exp Med       Date:  2015-11-15

2.  AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas.

Authors:  Moshe Elkabets; Evangelos Pazarentzos; Dejan Juric; Qing Sheng; Raphael A Pelossof; Samuel Brook; Ana Oaknin Benzaken; Jordi Rodon; Natasha Morse; Jenny Jiacheng Yan; Manway Liu; Rita Das; Yan Chen; Angela Tam; Huiqin Wang; Jinsheng Liang; Joseph M Gurski; Darcy A Kerr; Rafael Rosell; Cristina Teixidó; Alan Huang; Ronald A Ghossein; Neal Rosen; Trever G Bivona; Maurizio Scaltriti; José Baselga
Journal:  Cancer Cell       Date:  2015-04-13       Impact factor: 31.743

Review 3.  The role of TAM family receptors and ligands in the nervous system: From development to pathobiology.

Authors:  Bridget Shafit-Zagardo; Ross C Gruber; Juwen C DuBois
Journal:  Pharmacol Ther       Date:  2018-03-04       Impact factor: 12.310

4.  Tumor-secreted Pros1 inhibits macrophage M1 polarization to reduce antitumor immune response.

Authors:  Eric Ubil; Laura Caskey; Alisha Holtzhausen; Debra Hunter; Charlotte Story; H Shelton Earp
Journal:  J Clin Invest       Date:  2018-04-30       Impact factor: 14.808

5.  TYRO3 induces anti-PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis.

Authors:  Zhou Jiang; Seung-Oe Lim; Meisi Yan; Jennifer L Hsu; Jun Yao; Yongkun Wei; Shih-Shin Chang; Hirohito Yamaguchi; Heng-Huan Lee; Baozhen Ke; Jung-Mao Hsu; Li-Chuan Chan; Gabriel N Hortobagyi; Liuqing Yang; Chunru Lin; Dihua Yu; Mien-Chie Hung
Journal:  J Clin Invest       Date:  2021-04-15       Impact factor: 14.808

Review 6.  Phosphatidylserine Is the Signal for TAM Receptors and Their Ligands.

Authors:  Greg Lemke
Journal:  Trends Biochem Sci       Date:  2017-07-19       Impact factor: 13.807

7.  A critical role of Gas6/Axl signal in allergic airway responses during RSV vaccine-enhanced disease.

Authors:  Takehiko Shibata; Manabu Ato
Journal:  Immunol Cell Biol       Date:  2017-07-19       Impact factor: 5.126

8.  Mer Tyrosine Kinase Regulates Disseminated Prostate Cancer Cellular Dormancy.

Authors:  Frank C Cackowski; Matthew R Eber; James Rhee; Ann M Decker; Kenji Yumoto; Janice E Berry; Eunsohl Lee; Yusuke Shiozawa; Younghun Jung; Julio A Aguirre-Ghiso; Russell S Taichman
Journal:  J Cell Biochem       Date:  2016-11-10       Impact factor: 4.429

9.  The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer.

Authors:  Jane Antony; Elisa Zanini; Zoe Kelly; Tuan Zea Tan; Evdoxia Karali; Mohammad Alomary; Youngrock Jung; Katherine Nixon; Paula Cunnea; Christina Fotopoulou; Andrew Paterson; Sushmita Roy-Nawathe; Gordon B Mills; Ruby Yun-Ju Huang; Jean Paul Thiery; Hani Gabra; Chiara Recchi
Journal:  EMBO Rep       Date:  2018-06-15       Impact factor: 8.807

10.  Triple Therapy with MerTK and PD1 Inhibition Plus Radiotherapy Promotes Abscopal Antitumor Immune Responses.

Authors:  Mauricio S Caetano; Ahmed I Younes; Hampartsoum B Barsoumian; Michael Quigley; Hari Menon; Chan Gao; Thomas Spires; Timothy P Reilly; Alexandra P Cadena; Taylor R Cushman; Jonathan E Schoenhals; Ailin Li; Quynh-Nhu Nguyen; Maria Angelica Cortez; James W Welsh
Journal:  Clin Cancer Res       Date:  2019-09-20       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.